

## Biophytis announces its participation in several conferences in Europe and the US during the first quarter of 2024

**Paris (France) and Cambridge (Massachusetts, USA), December 11, 2023 – 07am CET** – Biophytis SA (Nasdaq CM : BPTS, Euronext Growth Paris : ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related neuromuscular and respiratory diseases, announces that it will take part in several conferences during the first quarter of 2024.

Biophytis management will be in San Francisco for meetings with potential partners and investors at the 42<sup>nd</sup> JP Morgan Healthcare Conference, to be held from 8 to 11 January 2024.

In addition, the company will be present:

- at the *Invest Securities Biomed Event* on 30 January 2024 in Paris,
- and at the *BIO-Europe Spring* conference from 18 to 20 March 2024 in Barcelona.

The **JP Morgan Healthcare Conference** is the world's largest healthcare investment event, bringing together the world's leading healthcare companies, biotechs and innovative technology developers with members of the international financial community.

**Invest Securities' Biomed Event** is an annual forum dedicated to the healthcare sector, bringing together biotechs or medtechs, pharmaceutical companies and institutional investors in one-to-one formats.

**BIO-Europe Spring** is the top event dedicated to partnerships in the life sciences, bringing together more than 3,700 participants, including over 2,000 companies, and connecting the global biopharmaceutical community through thousands of meetings.

\* \* \* \*

### About BIOPHYTIS

Biophytis SA is a clinical-stage biotechnology company specializing in the development of drug candidates for age-related diseases. Sarconeos (BIO101), our lead drug candidate, is a small molecule in development for age-related neuromuscular (sarcopenia and Duchenne muscular dystrophy) and cardiorespiratory (Covid-19) diseases. Promising clinical results were obtained in the treatment of sarcopenia in an international phase 2 study, enabling the launch of a phase 3 study in this indication (SARA project). The safety and efficacy of Sarconeos (BIO101) in the treatment of severe COVID-19 were studied in a positive



## Press release

international phase 2-3 clinical trial (COVA project). A pediatric formulation of Sarconeos (BIO101) is currently being developed for the treatment of Duchenne Muscular Dystrophy (DMD, MYODA project). The company is based in Paris, France, and Cambridge, Massachusetts. The Company's ordinary shares are listed on Euronext Growth (Ticker: ALBPS -ISIN: FR0012816825) and the ADSs (American Depositary Shares) are listed on Nasdaq Capital Market (Ticker BPTS - ISIN: US09076G1040).

For more information, visit [www.biophytis.com](http://www.biophytis.com)

### Disclaimer

This press release contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. In some cases, you can identify these forward-looking statements by the use of words such as "outlook," "believes," "expects," "potential," "continues," "may," "will," "should," "could," "seeks," "predicts," "intends," "trends," "plans," "estimates," "anticipates" or the negative version of these words or other comparable words. Such forward-looking statements are based on assumptions that Biophytis considers to be reasonable. However, there can be no assurance that the statements contained in such forward-looking statements will be verified, which are subject to various risks and uncertainties. The forward-looking statements contained in this press release are also subject to risks not yet known to Biophytis or not currently considered material by Biophytis. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. Please also refer to the "Risk and uncertainties the Company is to face» section from the Company's 2022 Financial Report available on BIOPHYTIS website ([www.biophytis.com](http://www.biophytis.com)) and as exposed in the "Risk Factors" section of form 20-F as well as other forms filed with the SEC (Securities and Exchange Commission, USA). We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law.

### Biophytis contacts

#### Investor relations

Nicolas Fellmann, CFO  
[Investors@biophytis.com](mailto:Investors@biophytis.com)

#### Media

Antoine Denry: [antoine.denry@taddeo.fr](mailto:antoine.denry@taddeo.fr) – +33 6 18 07 83 27  
Nizar Berrada: [nizar.berrada@taddeo.fr](mailto:nizar.berrada@taddeo.fr) – +33 6 38 31 90 50